The global blood cancer drugs market size was worth US$ 38,256.0 million in 2020 and is estimated to reach US$ YY million by 2028, growing at a CAGR of 7.0% during the forecast period (2021-2028).
Blood cancer is a serious and life-threatening cancer that affects either production or function of blood cells such as bone marrow and tissues which results in dysfunction of the lymphatic system.
By type , the blood cancer drugs market is classified into leukemia, lymphoma, and myeloma. Leukemia segment is expected to grow at the fastest CAGR during the forecast period (2021-2028). Leukemia is a blood cancer that originates in the blood and bone marrow. It occurs when the body creates too many abnormal white blood cells and interferes with the bone marrow’s ability to make red blood cells and platelets.
On the basis of drugs type, the the blood cancer drugs market is classified into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Others. The Rituaxan/Mabthera (Rituximab) drugs segment is expected to hold a share of about 12.6% in 2020 in the blood cancer drugs market. The Mabthera was the first therapeutic monoclonal antibody to target cells that have the CD20 marker on their surface. These cells are central to many blood cancers, including common forms of lymphoma and leukaemia. Mabthera attacks these cells both directly and together with the body’s immune system.
Market Dynamics
Drivers
- The growing death incidences and increasing prevalence of blood cancer cases across the globe
- Formulations of new regulatory approvals for new drugs for blood cancer are expected to drive the growth
Restraints
- High drug approval costs hinders the growth of the blood cancer drugs market
By type , the blood cancer drugs market is classified into leukemia, lymphoma, and myeloma. Leukemia segment is expected to grow at the fastest CAGR during the forecast period
The drugs market for hodgkin lymphoma was valued at USD YY million in 2020 and the market is estimated to grow at a CAGR of 7.4% in the forecast period to reach a market value of USD YY million by 2028.
Hodgkin's lymphoma is a malignant tumor that develops from cells in the lymphatic system called lymphocytes. The cancer is characterized histologically by the presence of multinucleated giant cells called Reed-Sternberg cells and associated abnormal, smaller mononuclear cells originating from B-lymphocytes in the germinal centers of lymphoid tissue.
Global statistics show that the number of new cases of Hodgkin’s lymphoma is 2.6 per 100,000 men and women, per year. Unlike most cancers, the chances of Hodgkin’s lymphoma do not increase with age; they are found to be high in two age groups, young adults and the elderly. The increase in the number of new cases diagnosed every year is expected to drive the Hodgkin’s lymphoma segment.
According to the American Cancer Society, in 2019, around 8,110 people in the United States were diagnosed with Hodgkin lymphoma.
According to the American Cancer Society estimates, in 2019, there were around 1,000 deaths (410 women and 590 men) from Hodgkin’s lymphoma in the United States. Hodgkin lymphoma affects both children and adults. It is the most commonly diagnosed cancer in teens aged 15 to 19 years.
Radiotherapy is a well-established technique at destroying Hodgkin’s disease cells by using high-energy beams or particles to kill cancer cells and may be delivered from a source outside the body, i.e., external beam radiation or internally, such as brachytherapy.
For classical Hodgkin’s disease, radiotherapy is often given after chemotherapy, especially when there is a large or bulky tumor mass.
Geographical Analysis
The Europe Blood Cancer Drugs market was valued at USD 10,665.8 million in 2020 and is estimated to reach USD YY million by 2028, at a CAGR of 7.1% during the forecast period (2021-2028). The region is also second in terms of blood cancer prevalence, next only to the United States.
The proportion of NH lymphoma and leukemia reached 44.93 and 34.90 in Europe. Western Europe in particular is leading with Germany, France and U.K. being the largest markets in incidence and prevalence rate.
The market value in Germany reached USD 2,330.1 million in 2020 and is likely to reach USD YY million by 2028. The growing number of chemotherapy procedures among children and adult population is driving the market. The incidence of leukemia in the country reached 13,700 in 2020 with Chromic Lymphocytic Leukemia (CLL) occupying 50% of these new cases. Also, Leukemia is the most frequent cancer among children and teenagers in Germany with a share of nearly 30% or annual incidence of 650 cases in 2020. Blood cancer treatment in Germany is highly advanced in Europe, serving large number of foreign patients with various types of blood cancers
The European Medicines Agency (EMA) regulates the development, clinical trials and approval of blood cancer drugs in the region. The market witnessed large number of new drug approvals by the EMA in recent years
- EMA granted a conditional marketing authorization for Abecma (idecabtagene vicleucel) for use in EU. Developed by Bristol Myers Squibb, this is used in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three previous therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody
- In July 2020, EMA’s human medicines committee (CHMP) recommended for the approval of GlaxoSmithKline plc developed belantamab mafodotin BLENREP. This is drug is for use in treatment of multiple myeloma
- In September 2017, Novartis’ Rydapt (midostaurin) got approval for use in combination with chemotherapy for acute myeloid leukemia (AML) in adults
The pandemic had a negative impact on the blood cancer drugs market, in that the cancer care in most of the major European markets is disrupted. The spread of the coronavirus affected the willingness of patients to visit healthcare facilities in wake of virus transmission. The EU, EMA and national Head of Medicines Agencies (HMA) have directed new recommendations for management of clinical trials during the pandemic situation, thereby ensure uninterrupted drug development activities in non-COVID medical care
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866
Website: www.datamintelligence.com